Tech Company Financing Transactions
Melinta Therapeutics Funding Round
Melinta Therapeutics, based in New Haven, secured $20 million in investment from Warburg Pincus and private investors.
Transaction Overview
Company Name
Announced On
1/11/2011
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Undisclosed
Investors
Warburg Pincus (Lead Investor) (Jonathan Leff)
Proceeds Purpose
In early 2011, we will begin a Phase 2b delafloxacin study to validate new objective endpoints for a near-term Phase 3 study and will initiate a long-term preclinical safety study with radezolid to demonstrate its key points of differentiation. We also expect to nominate an initial development candidate with activity against multi-drug resistant Gram-negative bacteria from our R?-04 program in early 2011.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
300 George St. 301
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Overview
Melinta Therapeutics' mission is to discover, develop and commercialize groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christine Miller
Chief Financial Officer
Peter Milligan
VP - Bus. Development
Michael McGuire
VP - Finance
Susan Blum
VP - General Counsel
Jennifer Sanfilippo
Browse more venture capital transactions:
Prev: 1/11/2011: AppFog venture capital transaction
Next: 1/11/2011: ProjectCenter venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs